Combined Use of a Novel Cardioplegic Formula With Myocardial Protection System (MPS)® Versus Cardioplexol ® in Isolated Coronary Artery Bypass Grafting (CABG) Using MiECC;

Combined Use of a Novel Cardioplegic Formula With MPS® Versus Cardioplexol ® in Isolated CABG Using MiECC (Minimal Extracorporeal Circulation System)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03612388

Acronym

MiECC

Enrollment

211

Registered

2018-08-02

Start date

2010-02-28

Completion date

2019-03-13

Last updated

2019-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Complication of Coronary Artery Bypass Graft, Complication of Extracorporeal Circulation

Brief summary

Combined use of a novel cardioplegic formula with MPS® (Myocardial protection system) versus Cardioplexol ® (colloid solution with Procaine, magnesium and potassium) in isolated CABG (coronary artery bypass grafting) using MiECC (Minimal extracorporeal circulation system).

Interventions

PROCEDUREuse of a cardioplegic formula in isolated CABG (coronary artery bypass grafting) using MiECC (Minimal extracorporeal circulation

use of a novel cardioplegic formula with MPS® (Myocardial protection system) versus Cardioplexol ® (colloid solution with Procaine, magnesium and potassium) in isolated CABG (coronary artery bypass grafting) using MiECC (Minimal extracorporeal circulation system).

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* CABG using MPS® or Cardioplexol ®

Exclusion criteria

* use of other colloid solution than Cardioplexol ® or MPS® * other inventions than CABG * myocardial infarction \<7 days before CABG * patients denial of data use

Design outcomes

Primary

Measure	Time frame	Description
Change in lab values for cardial biomarkers	perioperative during hospital stay for CABG	cardial biomarkers measured are high sensitive troponin T (hs-TrT), Creatinkinase, (CK) Creatinkinase myocardial type (CK-MB)

Secondary

Measure	Time frame	Description
mortality	30 days after CABG	death after coronary artery bypass grafting
need for intensive care unit	perioperative during hospital stay for CABG	duration of stay at intensive care unit
dysrhythmia	perioperative during hospital stay for CABG	rhythm disturbance after coronary artery bypass grafting
bleeding	perioperative during hospital stay for CABG	bleeding complication after coronary artery bypass grafting

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026